Interferon alpha 2b in the treatment of uveitic cystoid macular edema

Ocular Immunology and Inflammation

Volumn 20, Issue 2, 2012, Pages 86-90

  Butler, Nicholas J ^a   Suhler, Eric B ^b,c   Rosenbaum, James T ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Cystoid; Edema; Interferon alpha 2b; Macular; Uveitis

Indexed keywords

ALPHA2B INTERFERON; AZATHIOPRINE; BEVACIZUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; ANOREXIA; ARTHRALGIA; ASTHMA; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HAIR LOSS; HUMAN; JAW PAIN; LEUKOPENIA; LIVER FUNCTION TEST; MALAISE; MEDICAL RECORD REVIEW; MYALGIA; NAUSEA; PNEUMONIA; RETINA; RETINA MACULA CYSTOID EDEMA; REVIEW; SCLERA DISEASE; SIDE EFFECT; THICKNESS; UNITED STATES; URTICARIA; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

ADRENAL CORTEX HORMONES; ADULT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MACULAR EDEMA; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84858207532     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2011.645989     Document Type: Review

References (21)

1. Lardenoye CW, van Kooij B, Rothova A. Impact of macu-lar edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446-1449. (Pubitemid 44108170)
2. Okhravi N, lightman S. Cystoid macular edema in uveitis. Ocul Immunol Infamm. 2003;11:29-38. (Pubitemid 36918643)
3. Onal S, Kazokoglu H, Koc A, et al. long-term effcacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis.Arch Ophthalmol. 129:288-294.
4. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423-431. (Pubitemid 36399030)
5. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55-61.
6. Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: A new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786-791. (Pubitemid 44386101)
7. Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Effcacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906-913.
8. Sozzani S, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmunity. Autoimmunity. 43:196-203.
9. Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119:1077-1079. (Pubitemid 32652205)
10. Shimura M, Saito T, Yasuda K, Tamai M. Clinical course of macular edema in two cases of interferon-associated retin-opathy observed by optical coherence tomography. Jpn J Ophthalmol. 2005;49:231-234. (Pubitemid 40880066)
11. Gillies MC, Su T. Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvascular Res. 1995;49:277-288.
12. Deuter CM, Gelisken F, Stubiger N, Zierhut M, Doycheva D. Successful treatment of chronic pseudophakic macu-lar edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. Ocul Immunol Infamm. 19:216-218.
13. McHutchison JG, lawitz EJ, Shiffman Ml, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
14. Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in inter-feron-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther. 2007;26:369-376. (Pubitemid 47063155)
15. Becker MD, Heliligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89:1254-1257. (Pubitemid 41638860)
16. Hanley JP, Haydon GH. The biology of interferon-alpha and the clinical signifcance of anti-interferon antibodies. Leuk Lymphoma. 1998;29:257-268. (Pubitemid 28282323)
17. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis. 1991;163:882-885.
18. Garutti R. letter to U. S. Food and Drug Administration. 2004.
19. Von Wussow P, Hehlmann R, Hochhaus T, et al. Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia. J Interferon Res. 1994;14:217-219. (Pubitemid 24292481)
20. Hosoi H, Imai M, Yamanaka M. The interferon-alpha 2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-alpha 2a. J Gastroenterol Hepatol. 1992;7:411-416.
21. Pachner A. Anti-interferon antibodies: surprises and lessons. Lancet Neurol. 2004;3:515. (Pubitemid 39485855)